Shingrix Gets China Nod But Won’t Launch Until 2020 Amid Strong Demand
Following a priority review, Shingrix may become the next hit vaccine in China as millions seek preventative care, but GSK is being cautious over supply plans.
You may also be interested in...
GSK is betting on a new partnership to more quickly ramp up patient access to its vaccines in the potentially vast market of China, amid rising demand and competition.
As China enters a new growth spur for the health sector, underscored by faster product approvals, annual reimbursement coverage and strong demand for high-quality treatments, strategic planning and meticulous execution are more important than ever if companies want to win in the world's second-largest pharma market, says a new report.
A proposed revision to China's Drug Administration Law will crack down on GMP violations with hefty fines, while a dedicated law proposes additional scrutiny over imported vaccines.